Cargando…

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB

We compare the cellular efficacy of two selective and cell permeable inhibitors of the antiapoptotic kinase CK2. One inhibitor, CX-4945, is already in clinical trials as antitumor drug, while the other, TDB, has been recently successfully employed to demonstrate the implication of CK2 in cellular (d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girardi, Cristina, Ottaviani, Daniele, Pinna, Lorenzo A., Ruzzene, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628960/ https://www.ncbi.nlm.nih.gov/pubmed/26558259 http://dx.doi.org/10.1155/2015/185736

Ejemplares similares

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
por: Klink, Morgann, et al.
Publicado: (2021)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
por: Trembley, Janeen H., et al.
Publicado: (2021)

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells
por: Kim, Jiyeon, et al.
Publicado: (2013)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131
por: Vilardell, Jordi, et al.
Publicado: (2018)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2
por: Yadav, Anil Kumar, et al.
Publicado: (2022)

Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain
por: Ottaviani, Daniele, et al.
Publicado: (2017)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma
por: Liu, Xiangyu, et al.
Publicado: (2019)

Role of protein kinase CK2 in antitumor drug resistance
por: Borgo, Christian, et al.
Publicado: (2019)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

Targeting CK2 in cancer: a valuable strategy or a waste of time?
por: Salvi, Mauro, et al.
Publicado: (2021)

4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects
por: Birus, Robin, et al.
Publicado: (2021)

The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells
por: Di Maira, Giovanni, et al.
Publicado: (2019)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies
por: Salizzato, Valentina, et al.
Publicado: (2016)

Protein kinase CK2: a potential therapeutic target for diverse human diseases
por: Borgo, Christian, et al.
Publicado: (2021)

PB1810: SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Long, Huideng, et al.
Publicado: (2023)

Contribution of the CK2 Catalytic Isoforms α and α’ to the Glycolytic Phenotype of Tumor Cells
por: Zonta, Francesca, et al.
Publicado: (2021)

Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
por: Milicic, Anita, et al.
Publicado: (2012)

The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation
por: Cozza, Giorgio, et al.
Publicado: (2015)

OR02-2 CX-4945 as a Potential Drug for Adrenocortical Carcinoma That Induces Multiple Exon-Skipping and Circular RNA of NR5A1
por: Tanaka, Tomoko, et al.
Publicado: (2019)

Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells
por: Kreutzer, Jan N, et al.
Publicado: (2010)

Phosphorylation of p23-1 cochaperone by protein kinase CK2 affects root development in Arabidopsis
por: D’Alessandro, Stefano, et al.
Publicado: (2019)

Synthesis and Properties of a Selective Inhibitor of Homeodomain–Interacting Protein Kinase 2 (HIPK2)
por: Cozza, Giorgio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eh376eoggii72fbi9qq6b8vdso